Pharmafile Logo
Pharmafocus logo
Advanced Search

Teva

Showing 15 posts of 234 posts found.

teva_copy

Teva sells $15 billion in bonds to fund Allergan generics deal

July 19, 2016
Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics

Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …

News
teva_copy

Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports

July 15, 2016
Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal

Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …

News
teva_copy

Mayne Pharma to buy a portfolio of Teva’s generic drugs for $652 million

June 29, 2016
Research and Development, Sales and Marketing Allergan, Deals, Mayne Pharma, Teva, generics, merger and acquisition

Australia’s Mayne Pharma Group Ltd (ASX: MYX) said it will acquire US generic products from Israel-based drugmaker Teva Pharmaceuticals (NYSE: …

News
teva_copy

Impax to acquire Teva, Allergan generic drugs for $586 million

June 22, 2016
Research and Development, Sales and Marketing Allergan, Impax, Teva, generics

Impax Laboratories (NASDAQ: IPXL) has announced that it has entered into agreements with Teva and affiliates of Allergan to acquire …

News
teva_copy

Teva returns rights to heart cell therapy to Mesoblast

June 16, 2016
Research and Development, Sales and Marketing Mesoblast, Teva, chronic heart failure, phase III

Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …

News
teva_copy

FDA asks Teva for further study on Huntington drug candidate

June 1, 2016
Medical Communications, Research and Development Huntington disease, Teva, US FDA, regulation

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) said the US regulators have put on hold the approval for its drug to …

News
takeda

Takeda, Teva name Hiroshi Matsumori CEO of Japanese generic drug joint venture

April 4, 2016
Business Services, Sales and Marketing CEO Appointment, Takeda, Teva, joint venture

Japanese drug firm Takeda (TYO: 4502) and Israel-based Teva (NYSE: TEVA) named Hiroshi Matsumori the chief executive for their newly-formed …

Appointment
teva_copy

Teva announces FDA approval for asthma injection, Cinqair

March 24, 2016
Research and Development, Sales and Marketing FDA, Teva, approval, asthma, cinqair

The US Food and Drug Administration has approved Cinqair (reslizumab), an injection for patients with severe asthma developed by Teva …

News
teva_copy

Teva says closing buy of Allergan’s generics biz may take longer

March 16, 2016
Business Services, Research and Development, Sales and Marketing Allergan, M&A, MA, Pfizer, Teva

Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) said its $40.5 billion acquisition of Allergan’s generics business will take longer than expected, …

News
ivf_worldwide_teva_logos

Teva funds research to protect fertility in women diagnosed with cancer

March 11, 2016
Business Services, Research and Development Cancer, IVF Worldwide, Teva, fertility, radiotherapy

Israeli generics giant Teva has announced it will support IVF-Worldwide with a research grant to improve knowledge of fertility preservation …

News

FDA grants approval for first generic version of Viagra

March 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing FDA, Pfizer, Teva, erectile dysfunction, generic, viagra

The US Food and Drug Administration (FDA) has granted approval to the first generic version of Pfizer’s blockbuster erectile dysfunction …

News
teva_copy

Teva issues US recall of amikacin sulfate injection due to glass identified in vials

March 10, 2016
Manufacturing and Production Teva, amikacin sulfate, glass, recall

Teva Pharmaceuticals has announced a voluntary recall of one lot of amikacin sulfate injection USP vials due to the potential …

News
teva_copy

Teva suffers EpiPen generic setback after FDA rejection

March 4, 2016
Medical Communications, Research and Development FDA, Teva, analphylaxis, approval, auto injector, auto-injector, rejection

The release of Teva Pharmaceuticals generic for the anaphylaxis treatment, EpiPen (epinephrine), is now expected to be severely delayed after …

News
Brandicourt

Sanofi plans R&D jobs cuts in France

February 3, 2016
Manufacturing and Production, Research and Development Sanofi, Teva, cuts, job losses, olivier brandicourt, redundancies

Sanofi chief executive Olivier Brandicourt is reported to be planning hundreds of job cuts across the firm’s base in France, …

News
UK flag

Teva launches biosimilar fertility treatment in the UK

January 8, 2016
Manufacturing and Production, Sales and Marketing Ovaleap, Teva, biosimilar

Teva has launched its biosimilar version of Merck’s fertility treatment Gonal-f in the UK, potentially bringing a more affordable version …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026